- N4 Pharma said it planned to conduct new and altered experiments for its vaccine delivery product, after original tests produced inconsistent efficacy results.

The company said it had commissioned the University of Queensland, or UQ, to repeat its original studies to demonstrate repeated strong antibody response with a standard test antigen.

In doing so, UQ would also document clearly the preparation steps for the treatment prior to injection.

In addition, the company said it would expand the study to include further variables to strengthen the depth of data to emerge from the work.

The new work was expected to take three-to-four months to conclude and for the results to be documented.

In the meantime, the company said its directors were actively reviewing all other work streams to put on hold any other non-essential studies not already commenced.

'In reviewing our various data sets and talking to our partners, it has become clear that the most expeditous route to progressing Nuvec is to revert to source and the work of UQ,' chief executive Nigel Theobald said.

'The team at UQ know Nuvec better than anyone and we feel confident that a positive repeat study, clearly documented with respect to methodology, will greatly aid other CROs in their studies.'

'Whist it is a disappointing decision to put other work on hold, doing so keeps the company well funded to do our future planned work once we have a better documented handling and preparation protocol from UQ.'

At 8:33am: (LON:N4P) N4 Pharma Plc Ord 0.4p share price was +0.05p at 4.4p

Story provided by